This page provides updates and analysis about the Inflation Reduction Act and the ways it could change how government pays for pharmaceuticals and biologics. We focus in particular on the new Medicare price negotiation program, inflation-based rebates, and other changes to how Medicare covers and pays for drugs, including prescription drug benefits for seniors.
First 10 Drugs Selected for IRA Negotiation (August 29, 2023)
Latest Updates (August 28, 2023) by Alex Lu & Matt Wetzel
Updates & Analysis
Webinar: Analysis by Goodwin partner Matt Wetzel on a panel hosted by the UK BioIndustry Association
Article: Analysis by Goodwin partner Matt Wetzel, published by the Washington Legal Foundation
Webinar: Analysis by Goodwin partner Matt Wetzel on a panel hosted by the Washington Legal Foundation
As companies and stakeholders challenge the implementation of the Inflation Reduction Act’s drug price negotiation program, we have tracked the key filings and allegations contained in these matters, including key pleadings and responses from the government.
Goodwin’s IRA Litigation Tracker
Legal Challenges to the Inflation Reduction Act Webinar
Lead Editor
- /en/people/w/wetzel-matt
Matt Wetzel
PartnerLife Sciences Regulatory & Compliance
Contributing Editor
- /en/people/l/lu-alexandra
Alexandra Lu
Partner